Seminars in Nephrology
Volume 24, Issue 3 , Pages 197-217 , May 2004

Pathogenesis of IgA nephropathy

  • Jonathan Barratt

      Affiliations

    • Department of Nephrology, Leicester General Hospital, Leicester, UK
    • ,
  • John Feehally

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Professor John Feehally, Department of Nephrology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4 PW, UK
    • Department of Nephrology, Leicester General Hospital, Leicester, UK
    • ,
  • Alice C Smith

      Affiliations

    • Department of Nephrology, Leicester General Hospital, Leicester, UK

References 

  1. Floege J, Burg M, Kliem V. Recurrent IgA nephropathy after kidney transplantation (Not a benign condition). Nephrol Dial Transplant. 1998;13:1933–1935
  2. Cuevas X, Lloveras J, Mir M, et al.  Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc. 1987;19:2208–2209
  3. Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation. 1982;33:370–376
  4. Viertel A, Weidmann E, Rickerts V, et al.  Renal involvement in HIV-infection. Results from the Frankfurt AIDS Cohort Study (FACS) and a review of the literature. Eur J Med Res. 2000;5:185–198
  5. Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?. Kidney Int. 2001;59:823–834
  6. Kerr MA. The structure and function of human IgA. Biochem J. 1990;271:285–296
  7. Johansen FE, Braathen R, Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand J Immunol. 2000;52:240–248
  8. Russell MW, Kilian M, Lamm ME. Biological activities of IgA. In:  Mestecky J,  Bienenstock J,  McGhee J,  Lamm M,  Strober W,  Ogra P editor. Mucosal Immunology. ed 2. San Diego: Academic Press; 1999;p. 225–240
  9. Mestecky J, Russell MW, Elson CO. Intestinal IgA (Novel views on its function in the defence of the largest mucosal surface). Gut. 1999;44:2–5
  10. Layward L, Allen AC, Hattersley JM, et al.  Low antibody affinity restricted to the IgA isotype in IgA nephropathy. Clin Exp Immunol. 1994;95:35–41
  11. Lycke N. T cell and cytokine regulation of the IgA response. Chem Immunol. 1998;71:209–234
  12. Defrance T, Vanbervliet B, Briere F, et al.  Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med. 1992;175:671–682
  13. Fujihashi K, Kweon MN, Kiyono H, et al.  A T cell/B cell/epithelial cell Internet for mucosal inflammation and immunity. Springer Semin Immunopathol. 1997;18:477–494
  14. Abreu-Martin MT, Targan SR. Regulation of immune responses of the intestinal mucosa. Crit Rev Immunol. 1996;16:277–309
  15. Brandtzaeg P, Farstad IN, Johansen FE, et al.  The B-cell system of human mucosae and exocrine glands. Immunol Rev. 1999;171:45–87
  16. Wiedle G, Dunon D, Imhof BA. Current concepts in lymphocyte homing and recirculation. Crit Rev Clin Lab Sci. 2001;38:1–31
  17. Pabst R, Binns RM. In vivo labelling of the spleen and mesenteric lymph nodes with fluorescein isothiocyanate for lymphocyte migration studies. Immunology. 1981;44:321–329
  18. Pabst R, Reynolds JD. Peyer’s patches export lymphocytes throughout the lymphoid system in sheep. J Immunol. 1987;139:3981–3985
  19. Alley CD, Kiyono H, McGhee JR. Murine bone marrow IgA responses to orally administered sheep erythrocytes. J Immunol. 1986;136:4414–4419
  20. Simecka JW. Mucosal immunity of the gastrointestinal tract and oral tolerance. Adv Drug Deliv Rev. 1998;34:235–259
  21. Roncarolo MG, Bacchetta R, Bordignon C, et al.  Type 1 T regulatory cells. Immunol Rev. 2001;182:68–79
  22. Ke Y, Pearce K, Lake JP, et al.  Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol. 1997;158:3610–3618
  23. Fujihashi K, McGhee JR, Kweon MN, et al.  Gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med. 1996;183:1929–1935
  24. Chao CC, Sandor M, Dailey MO. Expression and regulation of adhesion molecules by gamma delta T cells from lymphoid tissues and intestinal epithelium. Eur J Immunol. 1994;24:3180–3187
  25. Lim SP, Leung E, Krissansen GW. The beta7 integrin gene (Itgb-7) promoter is responsive to TGF-beta1 (Defining control regions). Immunogenetics. 1998;48:184–195
  26. van Egmond M, van Garderen E, van Spriel AB, et al.  FcalphaRI-positive liver Kupffer cells (Reappraisal of the function of immunoglobulin A in immunity). Nat Med. 2000;6:680–685
  27. Rifai A, Schena FP, Montinaro V, et al.  Clearance kinetics and fate of macromolecular IgA in patients with IgA nephropathy. Lab Invest. 1989;61:381–388
  28. Rifai A, Fadden K, Morrison SL, et al.  The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med. 2000;191:2171–2182
  29. Grossetete B, Launay P, Lehuen A, et al.  Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients (Evidence for a negative regulatory role of serum IgA). Kidney Int. 1998;53:1321–1335
  30. Feehally J. Immune mechanisms in glomerular IgA deposition. Nephrol Dial Transplant. 1988;3:361–378
  31. Harada T, Hobby P, Courteau M, et al.  Charge distribution of plasma IgA in IgA nephropathy. Clin Exp Immunol. 1989;77:211–214
  32. Monteiro RC, Chevailler A, Noel LH, et al.  Serum IgA preferentially binds to cationic polypeptides in IgA nephropathy. Clin Exp Immunol. 1988;73:300–306
  33. Lam CW, Chui SH, Leung NW, et al.  Light chain ratios of serum immunoglobulins in disease. Clin Biochem. 1991;24:283–287
  34. Allen A, Feehally J. IgA glycosylation in IgA nephropathy. Adv Exp Med Biol. 1998;435:175–183
  35. Allen AC. Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy. J Nephrol. 1999;12:76–84
  36. Mestecky J, Tomana M, Crowley-Nowick PA, et al.  Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol. 1993;104:172–182
  37. Allen AC, Bailey EM, Barratt J, et al.  Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol. 1999;10:1763–1771
  38. Hiki Y, Iwase H, Kokubo T, et al.  Association of asialo-galactosyl beta 1–3N-acetylgalactosamine on the hinge with a conformational instability of Jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy. J Am Soc Nephrol. 1996;7:955–960
  39. Hiki Y, Tanaka A, Kokubo T, et al.  Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol. 1998;9:577–582
  40. Hiki Y, Odani H, Takahashi M, et al.  Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001;59:1077–1085
  41. Leung JC, Tang SC, Chan DT, et al.  Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy. J Clin Lab Anal. 2002;16:11–19
  42. Boehm MK, Woof JM, Kerr MA, et al.  The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG (a study by x-ray and neutron solution scattering and homology modelling). J Mol Biol. 1999;286:1421–1447
  43. Kokubo T, Hiki Y, Iwase H, et al.  Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol. 1998;9:2048–2054
  44. O’Donoghue DJ, Feehally J. Autoantibodies in IgA nephropathy. Contrib Nephrol. 1995;111:93–103
  45. Layward L, Allen AC, Hattersley JM, et al.  Elevation of IgA in IgA nephropathy is localized in the serum and not saliva and is restricted to the IgA1 subclass. Nephrol Dial Transplant. 1993;8:25–28
  46. van den Wall Bake AW, Beyer WE, Evers-Schouten JH, et al.  Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies. J Clin Invest. 1989;84:1070–1075
  47. Layward L, Allen AC, Harper SJ, et al.  Increased and prolonged production of specific polymeric IgA after systemic immunization with tetanus toxoid in IgA nephropathy. Clin Exp Immunol. 1992;88:394–398
  48. Fortune F, Courteau M, Williams DG, et al.  T and B cell responses following immunization with tetanus toxoid in IgA nephropathy. Clin Exp Immunol. 1992;88:62–67
  49. Kokubo T, Hashizume K, Iwase H, et al.  Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transplant. 2000;15:28–33
  50. Tomana M, Novak J, Julian BA, et al.  Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81
  51. Roccatello D, Picciotto G, Coppo R, et al.  The fate of aggregated immunoglobulin A injected in IgA nephropathy patients and healthy controls. Am J Kidney Dis. 1991;18:20–25
  52. Leung JC, Tsang AW, Chan LY, et al.  Size-dependent binding of IgA to HepG2, U937, and human mesangial cells. J Lab Clin Med. 2002;140:398–406
  53. van Zandbergen G, van Kooten C, Mohamad NK, et al.  Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. Nephrol Dial Transplant. 1998;13:3058–3064
  54. Hisano S, Matsushita M, Fujita T, et al.  Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis. 2001;38:1082–1088
  55. Feehally J, Allen AC. Pathogenesis of IgA nephropathy. Ann Med Interne (Paris). 1999;150:91–98
  56. Allen AC, Bailey EM, Brenchley PE, et al.  Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation (Observations in three patients). Kidney Int. 2001;60:969–973
  57. Leinikki PO, Mustonen J, Pasternack A. Immune response to oral polio vaccine in patients with IgA glomerulonephritis. Clin Exp Immunol. 1987;68:33–38
  58. Barratt J, Bailey EM, Buck KS, et al.  Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis. 1999;33:1049–1057
  59. Ots M, Uibo O, Metskula K, et al.  IgA-antigliadin antibodies in patients with IgA nephropathy (The secondary phenomenon?). Am J Nephrol. 1999;19:453–458
  60. Westberg NG, Baklien K, Schmekel B, et al.  Quantitation of immunoglobulin-producing cells in small intestinal mucosa of patients with IgA nephropathy. Clin Immunol Immunopathol. 1983;26:442–445
  61. Harper SJ, Pringle JH, Wicks AC, et al.  Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int. 1994;45:836–844
  62. de Fijter JW, Eijgenraam JW, Braam CA, et al.  Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int. 1996;50:952–961
  63. van den Wall Bake AW, Daha MR, Evers-Schouten J, et al.  Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy (Evidence for the bone marrow as the source of mesangial IgA). Am J Kidney Dis. 1988;12:410–414
  64. Harper SJ, Allen AC, Pringle JH, et al.  Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol. 1996;49:38–42
  65. Layward L, Finnemore AM, Allen AC, et al.  Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy. Clin Immunol Immunopathol. 1993;69:306–313
  66. Ichinose H, Miyazaki M, Koji T, et al.  Detection of cytokine mRNA-expressing cells in peripheral blood of patients with IgA nephropathy using non-radioactive in situ hybridization. Clin Exp Immunol. 1996;103:125–132
  67. Lai KN, Ho RT, Lai CK, et al.  Increase of both circulating Th1 and Th2 T lymphocyte subsets in IgA nephropathy. Clin Exp Immunol. 1994;96:116–121
  68. Ebihara I, Hirayama K, Yamamoto S, et al.  Th2 predominance at the single-cell level in patients with IgA nephropathy. Nephrol Dial Transplant. 2001;16:1783–1789
  69. Lai KN, Ho RT, Leung JC, et al.  Increased mRNA encoding for transforming factor-beta in CD4+ cells from patients with IgA nephropathy. Kidney Int. 1994;46:862–868
  70. de Caestecker MP, Bottomley M, Telfer BA, et al.  Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Kidney Int. 1993;44:1298–1308
  71. de Fijter JW, Daha MR, Schroeijers WE, et al.  Increased IL-10 production by stimulated whole blood cultures in primary IgA nephropathy. Clin Exp Immunol. 1998;111:429–434
  72. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995;100:470–474
  73. Greer MR, Barratt J, Harper SJ, et al.  The nucleotide sequence of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transplant. 1998;13:1980–1983
  74. Allen AC, Topham PS, Harper SJ, et al.  Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant. 1997;12:701–706
  75. Pierce-Cretel A, Pamblanco M, Strecker G, et al.  Heterogeneity of the glycans O-glycosidically linked to the hinge region of secretory immunoglobulins from human milk. Eur J Biochem. 1981;114:169–178
  76. Chintalacharuvu SR, Emancipator SN. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol. 1997;159:2327–2333
  77. Feehally J, Beattie TJ, Brenchley PE, et al.  Response of circulating immune complexes to food challenge in relapsing IgA nephropathy. Pediatr Nephrol. 1987;1:581–586
  78. Nagy J, Scott H, Brandtzaeg P. Antibodies to dietary antigens in IgA nephropathy. Clin Nephrol. 1988;29:275–279
  79. Rostoker G, Petit-Phar M, Delprato S, et al.  Mucosal immunity in primary glomerulonephritis (II. Study of the serum IgA subclass repertoire to food and airborne antigens). Nephron. 1991;59:561–566
  80. Kennel A, Bene MC, Hurault de Ligny B, et al.  Serum anti-dextran antibodies in IgA nephropathy. Clin Nephrol. 1995;43:216–220
  81. Rantala I, Collin P, Holm K, et al.  Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. Kidney Int. 1999;55:2274–2280
  82. Rostoker G, Delchier JC, Chaumette MT. Increased intestinal intra-epithelial T lymphocytes in primary glomerulonephritis (A role of oral tolerance breakdown in the pathophysiology of human primary glomerulonephritides?). Nephrol Dial Transplant. 2001;16:513–517
  83. Olive C, Allen AC, Harper SJ, et al.  Expression of the mucosal gamma delta T cell receptor V region repertoire in patients with IgA nephropathy. Kidney Int. 1997;52:1047–1053
  84. Buck KS, Foster EM, Watson D, et al.  Expression of T cell receptor variable region families by bone marrow gammadelta T cells in patients with IgA nephropathy. Clin Exp Immunol. 2002;127:527–532
  85. Toyabe S, Harada W, Uchiyama M. Oligoclonally expanding gammadelta T lymphocytes induce IgA switching in IgA nephropathy. Clin Exp Immunol. 2001;124:110–117
  86. Schlondorff D. The glomerular mesangial cell (An expanding role for a specialized pericyte). FASEB J. 1987;1:272–281
  87. Schlondorff D, Mori T. Contributions of mesangial cells to glomerular immune functions. Klin Wochenschr. 1990;68:1138–1144
  88. Waldherr R, Rambausek M, Duncker WD, et al.  Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant. 1989;4:943–946
  89. Hotta O, Furuta T, Chiba S, et al.  Regression of IgA nephropathy (A repeat biopsy study). Am J Kidney Dis. 2002;39:493–502
  90. Zickerman AM, Allen AC, Talwar V, et al.  IgA myeloma presenting as Henoch-Schönlein purpura with nephritis. Am J Kidney Dis. 2000;36:E19
  91. Launay P, Grossetete B, Arcos-Fajardo M, et al.  Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med. 2000;191:1999–2009
  92. Van Der Boog PJ, De Fijter JW, Van Kooten C, et al.  Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy. Kidney Int. 2003;63:514–521
  93. Tomino Y, Endoh M, Nomoto Y, et al.  Specificity of eluted antibody from renal tissues of patients with IgA nephropathy. Am J Kidney Dis. 1982;1:276–280
  94. Orfila C, Rakotoarivony J, Manuel Y, et al.  Immunofluorescence characterization of light chains in human nephropathies. Virchows Arch A Pathol Anat Histopathol. 1988;412:591–594
  95. Moura IC, Centelles MN, Arcos-Fajardo M, et al.  Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med. 2001;194:417–425
  96. Haddad E, Moura IC, Arcos-Fajardo M, et al.  Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis (Association between CD71 expression and IgA deposits). J Am Soc Nephrol. 2003;14:327–337
  97. Gomez-Guerrero C, Duque N, Egido J. Mesangial cells possess an asialoglycoprotein receptor with affinity for human immunoglobulin A. J Am Soc Nephrol. 1998;9:568–576
  98. McDonald KJ, Cameron AJ, Allen JM, et al.  Expression of Fc alpha/mu receptor by human mesangial cells (a candidate receptor for immune complex deposition in IgA nephropathy). Biochem Biophys Res Commun. 2002;290:438–442
  99. Barratt J, Greer MR, Pawluczyk IZ, et al.  Identification of a novel Fcalpha receptor expressed by human mesangial cells. Kidney Int. 2000;57:1936–1948
  100. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, et al.  Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol. 1994;153:5247–5255
  101. Yan D, Rumbeiha WK, Pestka JJ. Experimental murine IgA nephropathy following passive administration of vomitoxin-induced IgA monoclonal antibodies. Food Chem Toxicol. 1998;36:1095–1106
  102. Imasawa T, Utsunomiya Y, Kawamura T, et al.  Evidence suggesting the involvement of hematopoietic stem cells in the pathogenesis of IgA nephropathy. Biochem Biophys Res Commun. 1998;249:605–611
  103. Imasawa T, Nagasawa R, Utsunomiya Y, et al.  Bone marrow transplantation attenuates murine IgA nephropathy (Role of a stem cell disorder). Kidney Int. 1999;56:1809–1817
  104. Stad RK, Bruijn JA, van Gijlswijk-Janssen DJ, et al.  An acute model for IgA-mediated glomerular inflammation in rats induced by monoclonal polymeric rat IgA antibodies. Clin Exp Immunol. 1993;92:514–521
  105. Fujii K, Muller KD, Clarkson AR, et al.  The effect of IgA immune complexes on the proliferation of cultured human mesangial cells. Am J Kidney Dis. 1990;16:207–210
  106. Chen A, Chen WP, Sheu LF, et al.  Pathogenesis of IgA nephropathy (In vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion). J Pathol. 1994;173:119–126
  107. Lopez-Armada MJ, Gomez-Guerrero C, Egido J. Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells (Role of TGF-beta). J Immunol. 1996;157:2136–2142
  108. Peruzzi L, Amore A, Cirina P, et al.  Integrin expression and IgA nephropathy (in vitro modulation by IgA with altered glycosylation and macromolecular IgA). Kidney Int. 2000;58:2331–2340
  109. Monteiro RC, Moura IC, Launay P, et al.  Pathogenic significance of IgA receptor interactions in IgA nephropathy. Trends Mol Med. 2002;8:464–468
  110. Van Dixhoorn MG, Sato T, Muizert Y, et al.  Combined glomerular deposition of polymeric rat IgA and IgG aggravates renal inflammation. Kidney Int. 2000;58:90–99
  111. Amore A, Cirina P, Conti G, et al.  Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol. 2001;12:1862–1871
  112. Matsuda M, Shikata K, Wada J, et al.  Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron. 1998;80:408–413
  113. Hansch GM. The role of complement in mesangial cell damage. Nephrol Dial Transplant. 1993;8:4–5 [Editorial]
  114. Endo M, Ohi H, Ohsawa I, et al.  Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998;13:1984–1990
  115. Abe K, Miyazaki M, Koji T, et al.  Intraglomerular synthesis of complement C3 and its activation products in IgA nephropathy. Nephron. 2001;87:231–239
  116. Abe K, Miyazaki M, Koji T, et al.  Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int. 1998;54:120–130
  117. Moll S, Miot S, Sadallah S, et al.  No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int. 2001;59:160–168
  118. Yoshioka K, Takemura T, Aya N, et al.  Monocyte infiltration and cross-linked fibrin deposition in IgA nephritis and Henoch-Schönlein purpura nephritis. Clin Nephrol. 1989;32:107–112
  119. Arima S, Nakayama M, Naito M, et al.  Significance of mononuclear phagocytes in IgA nephropathy. Kidney Int. 1991;39:684–692
  120. Li HL, Hancock WW, Dowling JP, et al.  Activated (IL-2R+) intraglomerular mononuclear cells in crescentic glomerulonephritis. Kidney Int. 1991;39:793–798
  121. Johnson RJ. The glomerular response to injury (progression or resolution?). Kidney Int. 1994;45:1769–1782
  122. Floege J. Glomerular remodelling (Novel therapeutic approaches derived from the apparently chaotic growth factor network). Nephron. 2002;91:582–587
  123. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases (Is the podocyte the culprit?). Kidney Int. 1998;54:687–697
  124. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–1456
  125. Falk MC, Ng G, Zhang GY, et al.  Infiltration of the kidney by alpha beta and gamma delta T cells (Effect on progression in IgA nephropathy). Kidney Int. 1995;47:177–185
  126. Wu H, Zhang GY, Clarkson AR, et al.  Conserved T-cell receptor beta chain CDR3 sequences in IgA nephropathy biopsies. Kidney Int. 1999;55:109–119
  127. Wu H, Clarkson AR, Knight JF. Restricted gammadelta T-cell receptor repertoire in IgA nephropathy renal biopsies. Kidney Int. 2001;60:1324–1331
  128. D’Amico G. Natural history of idiopathic IgA nephropathy (Role of clinical and histological prognostic factors). Am J Kidney Dis. 2000;36:227–237
  129. Julian BA, Quiggins PA, Thompson JS, et al.  Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med. 1985;312:202–208
  130. Schena FP, Scivittaro V, Ranieri E, et al.  Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy. Clin Exp Immunol. 1993;92:139–144
  131. Hsu SI, Ramirez SB, Winn MP, et al.  Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000;57:1818–1835
  132. Wanstrat A, Wakeland E. The genetics of complex autoimmune diseases (Non-MHC susceptibility genes). Nat Immunol. 2001;2:802–809
  133. Gharavi AG, Yan Y, Scolari F, et al.  IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22–23. Nat Genet. 2000;26:354–357
  134. Field M. Tumour necrosis factor polymorphisms in rheumatic diseases. QJM. 2001;94:237–246
  135. Hutchinson IV, Pravica V, Perrey C, et al.  Cytokine gene polymorphisms and relevance to forms of rejection. Transplant Proc. 1999;31:734–736
  136. Koss K, Satsangi J, Fanning GC, et al.  Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls (Differential effects on production and allele frequencies). Genes Immunol. 2000;1:185–190
  137. Schena FP. Cytokine network and resident renal cells in glomerular diseases. Nephrol Dial Transplant. 1999;14:22–26
  138. Bidwell J, Keen L, Gallagher G, et al.  Cytokine gene polymorphism in human disease (On-line databases). Genes Immunol. 1999;1:3–19
  139. Kotb M, Norrby-Teglund A, McGeer A, et al.  An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med. 2002;8:1398–1404
  140. Akahoshi M, Nakashima H, Miyake K, et al.  Influence of interleukin-12 receptor beta1 polymorphisms on tuberculosis. Hum Genet. 2003;112:237–243
  141. Treszl A, Toth-Heyn P, Kocsis I, et al.  Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol. 2002;17:713–717
  142. Hutchings A, Benfield M, Thomas J. Associations between single nucleotide polymorphisms in cytokine genes and costimulatory molecule expression. Hum Immunol. 2002;63:S14
  143. Hutchings A, Guay-Woodford L, Thomas JM, et al.  Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant. 2002;6:69–77
  144. Boiardi L, Salvarani C, Casali B, et al.  Intercellular adhesion molecule-1 gene polymorphisms in Behcet’s disease. J Rheumatol. 2001;28:1283–1287
  145. Shu KH, Lee SH, Cheng CH, et al.  Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Kidney Int. 2000;58:783–789
  146. Syrjanen J, Hurme M, Lehtimaki T, et al.  Polymorphism of the cytokine genes and IgA nephropathy. Kidney Int. 2002;61:1079–1085
  147. Watanabe M, Iwano M, Akai Y, et al.  Association of interleukin-1 receptor antagonist gene polymorphism with IgA nephropathy. Nephron. 2002;91:744–746
  148. Masutani K, Miyake K, Nakashima H, et al.  Impact of interferon-gamma and interleukin-4 gene polymorphisms on development and progression of IgA nephropathy in Japanese patients. Am J Kidney Dis. 2003;41:371–379
  149. Schena FP, D’Altri C, Cerullo G, et al.  ACE gene polymorphism and IgA nephropathy (An ethnically homogeneous study and a meta-analysis). Kidney Int. 2001;60:732–740
  150. Yoon HJ, Kim H, Kim HL, et al.  Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. Clin Genet. 2002;62:128–134
  151. Mattu TS, Pleass RJ, Willis AC, et al.  The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions. J Biol Chem. 1998;273:2260–2272
  152. Novak J, Julian BA, Tomana M, et al.  Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol. 2001;21:310–327

PII: S0270-9295(04)00004-X

doi: 10.1016/j.semnephrol.2004.01.002

Seminars in Nephrology
Volume 24, Issue 3 , Pages 197-217 , May 2004

Article Tools

* Image Usage & Resolution